Approval · Notice of Compliance 9839 · 2008
TYSABRI: Notice of Compliance 9839
Issued October 17, 2008
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9839
- Date
- October 17, 2008
- Company
- Biogen Idec Canada Inc
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New manufacturing facility
- Therapeutic class
- Selective adhesion molecule inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TYSABRI | Not yet assigned | — |
Medicinal ingredients
- NATALIZUMAB 300 MG per 15ML